促红细胞生成素受体介导的分子串话促进T细胞免疫调节与移植存活
该研究探讨促红细胞生成素(EPO)是否具有免疫调节特性从而参与自发性肾移植耐受。体外实验显示EPO通过抗原提呈细胞上的EPO受体和CD131诱导活性TGFβ分泌,进而将初始CD4+ T细胞转化为功能性Foxp3+调节性T细胞。小鼠移植模型中药物下调肾脏来源EPO可阻止自发性Treg生成;在慢性肾脏病患者中,纠正贫血剂量的EPO可增加外周CD4+CD25+CD127lo T细胞频率;重组EPO可延长小鼠心脏移植物存活。
要点
- EPO通过抗原提呈细胞EPO受体/CD131促进活性TGFβ分泌并诱导Foxp3+ Treg生成。
- 药物下调肾脏来源EPO可阻止小鼠自发性Treg生成并消除肾移植耐受。
- 纠正贫血剂量的EPO可增加慢性肾脏病患者外周CD4+CD25+CD127lo T细胞频率。
核心结论
- EPO具有促耐受特性,既能抑制常规T细胞又促进Treg诱导,提示操纵EPO/EPO受体信号轴可能用于预防和/或治疗T细胞介导的病理状态包括移植排斥。
研究设计与样本
- 体外实验、小鼠移植模型以及一项对照前瞻性队列临床研究。
主要发现
- 体外EPO以依赖抗原提呈细胞EPO受体和CD131的方式诱导活性TGFβ分泌,并将初始CD4+ T细胞转化为功能性Foxp3+ Treg。
- 小鼠移植模型中药物下调肾脏来源EPO阻止自发性Treg生成,并降低TGFβ mRNA表达、消除肾移植耐受。
- 在慢性肾脏病患者中,用于纠正贫血剂量的EPO增加了外周CD4+CD25+CD127lo T细胞频率。
- 体外EPO通过酪氨酸磷酸酶SHP-1依赖性解偶联IL-2Rβ信号直接抑制常规T细胞增殖,同时通过增强IL-2Rγ信号和维持IL-2Rβ信号持续淬灭促进Treg增殖。
- 在小鼠移植模型中,重组EPO给药延长了心脏移植物存活。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although spontaneous kidney transplant acceptance/tolerance occurs in mice and occasionally in humans, mechanisms remain unclear. Herein we test the hypothesis that EPO, a hormone predominantly produced by the adult kidney, has immunomodulating properties that are required for spontaneous kidney graft acceptance. In vitro, in a manner dependent on the EPO receptor and CD131 on antigen-presenting cells, EPO induced the secretion of active TGFβ by antigen-presenting cells, which in turn converted naïve CD4+ T cells into functional Foxp3+ regulatory T cells (Treg). In murine transplant models, pharmacologic downregulation of kidney-derived EPO prevented spontaneous Treg generation. In a controlled, prospective cohort clinical study, EPO administration at doses used to correct anemia augmented the frequency of peripheral CD4+CD25+CD127lo T cells in humans with CKD. Furthermore, EPO directly inhibited conventional T cell proliferation in vitro via tyrosine phosphatase SHP-1-dependent uncoupling of IL-2Rβ signaling. Conversely, EPO-initiated signals facilitated Treg proliferation by augmenting IL-2Rγ signaling and maintaining constitutively quenched IL-2Rβ signaling. In additional murine transplant models, recombinant EPO administration prolonged heart allograft survival, whereas pharmacologic downregulation of kidney-derived EPO reduced the expression of TGFβ mRNA and abrogated kidney allograft acceptance. Together, our findings delineate the protolerogenic properties of EPO in inhibiting conventional T cells while simultaneously promoting Treg induction, and suggest that manipulating the EPO/EPO receptor signaling axis could be exploited to prevent and/or treat T cell-mediated pathologies, including transplant rejection.
引用
- Purroy C, Fairchild RL, Tanaka T, et al. Erythropoietin Receptor-Mediated Molecular Crosstalk Promotes T Cell Immunoregulation and Transplant Survival. J Am Soc Nephrol. 2017. PMID: 28302753. doi:10.1681/ASN.2016101100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。